AI assistant
IMUGENE LIMITED — Board/Management Information 2019
Apr 22, 2019
65124_rns_2019-04-22_80477203-3a42-404f-be73-86cba20ada89.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [116 x 41] intentionally omitted <==
ASX Announcement
Leading Global Pharmaceutical Executive Joins Imugene Board
SYDNEY Australia 23 April 2019: The Board of Imugene Limited (ASX: IMU) is pleased to announce the appointment of a leading global pharmaceutical executive Dr. Lesley Russell as a NonExecutive Director, effective 23 April 2019.
Dr. Lesley Russell has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.
Her experience has been gained at a number of leading companies including, Amgen (NASDAQ: AMGN), Eli Lilly (NASDAQ: LLY), US Bioscience/Medimmune Oncology, Cephalon Inc (NASDAQ: CEPH), Teva Pharmacaeuticals (NASDAQ: TEVA), TetraLogic and Innocoll Holdings Plc.
Dr. Lesley Russell is currently a Non-executive Director of AMAG Pharmaceuticals (NASDAQ:AMAG), Enanta Pharmaceuticals (NASDAQ:ENTA) and Sojournix a privately held biotechnology company. Dr. Lesley Russell was a non-executive director of Endocyte Pharmaceuticals Inc until its acquisition by Novartis in December, 2018.
Dr. Lesley Russell brings extensive pharamaceutical experience to the Board and has held Directorship roles including a number of cancer therapy collaborations with Teva Pharmaceuticals including CureTech which was developing a PD1 antibody, MGVS, which was developing a stem cell gene therapy for peripheral vascular disease, Teva/Lonza, a joint venture developing biosimilars and Cephalon Australia, developing monoclonal antibodies for cancer and inflammation targets.
Imugene Executive Chairman, Paul Hopper said: “Dr. Lesley Russell’s global industry knowledge and direct experience of oncology drug development and strategic joint ventures will further enhance the Board’s skill mix. We are delighted she is joining our business and look forward to her contributions as we work to advance our promising cancer vaccine pipeline.”
Subject to shareholder approval, the Company agrees to issue 25 million unlisted options exercisable at A$0.04 (5 mil options), A$0.042 (10 mil options) and A$0.045 (10 mil options) per option expiring 3 years from the date of approval to be vested over 24 months to Dr. Lesley Russell.
Following a Board review of its remuneration policies and to promote remuneration parity across the board, the Company has also agreed to issue 25 million unlisted options to its Non-Executive Directors, Mr. Charles Walker and Dr. Axel Hoos with the same terms and conditions as Dr. Lesley Russell, as a one off issue.
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected]
For further information please contact:
Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: [email protected]
Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
2
IMUGENE LIMITED ACN 009 179 551